1. Home
  2. XYF vs ENGN Comparison

XYF vs ENGN Comparison

Compare XYF & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo X Financial each representing six

XYF

X Financial each representing six

N/A

Current Price

$5.12

Market Cap

181.0M

Sector

Finance

ML Signal

N/A

Logo enGene Holdings Inc.

ENGN

enGene Holdings Inc.

N/A

Current Price

$1.98

Market Cap

117.2M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
XYF
ENGN
Founded
2014
1999
Country
China
Canada
Employees
N/A
N/A
Industry
Finance: Consumer Services
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
181.0M
117.2M
IPO Year
2018
2023

Fundamental Metrics

Financial Performance
Metric
XYF
ENGN
Price
$5.12
$1.98
Analyst Decision
Hold
Analyst Count
0
10
Target Price
N/A
★ $3.29
AVG Volume (30 Days)
68.0K
★ 662.0K
Earning Date
11-19-2026
09-08-2026
Dividend Yield
★ 10.88%
N/A
EPS Growth
N/A
★ 56.85
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.90
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.30
$1.40
52 Week High
$14.86
$12.25

Technical Indicators

Market Signals
Indicator
XYF
ENGN
Relative Strength Index (RSI) 47.68 58.34
Support Level $4.98 $1.67
Resistance Level $5.15 $2.08
Average True Range (ATR) 0.24 0.07
MACD 0.00 0.01
Stochastic Oscillator 58.18 71.43

Price Performance

Historical Comparison
XYF
ENGN

About XYF X Financial each representing six

X Financial is a Cayman Islands-based technology-driven personal finance company. Along with its subsidiaries, the firm provides diversified investment opportunities to investors in China through its wealth management platform, Xiaoying Wealth Management. Loan products offered by the company include Xiaoying Card Loan, Xiaoying Preferred Loan, and Xiaoying Housing Loan. The company generates revenue from loan facilitation service, post-origination service, guarantee services provided and financing income.

About ENGN enGene Holdings Inc.

enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

Share on Social Networks: